Digital therapeutics companies are eager to show their work.
Five days before President Biden took office, the Department of Health and Human Services proposed a rule to exempt a laundry list of medical devices from typical regulations, including newly cleared apps to treat psychiatric disorders. Now, their creators have pushed back, demanding that digital therapeutics need and deserve regulatory scrutiny.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Health Tech Correspondent
Katie Palmer is a health tech correspondent at STAT.